CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Strength||40 mg tablet|
|Indication||Metastatic Castration Resistant Prostate Cancer|
|Funding Request||For the treatment of patients with metastatic castration-resistant prostate cancer, who have previously received docetaxel therapy|
|Pre Noc Submission||Yes|
|NOC Date||May 29, 2013|
|Manufacturer||Astellas Pharma Canada Inc.|
|Sponsor||Astellas Pharma Canada Inc.|
|Submission Date||March 4, 2013|
|Submission Deemed Complete||March 19, 2013|
|Prioritization Requested||Not Requested|
|Stakeholder Input Deadline ‡||March 18, 2013|
|Check-point meeting||April 30, 2013|
|pERC Meeting||June 20, 2013|
|Initial Recommendation Issued||July 5, 2013|
|Feedback Deadline ‡||July 19, 2013|
|Final Recommendation Issued||July 23, 2013|
|Notification to Implement Issued||August 8, 2013|
|Therapeutic Area||Metastatic Castration Resistant Prostate Cancer|
|Recommendation Type||Reimburse with clinical criteria and/or conditions|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.